7-octadecynoic acid
7-octadecynoic acid is a lipid of Fatty Acyls (FA) class.
Cross Reference
There are no associated biomedical information in the current reference collection.
Current reference collection contains 19785 references associated with 7-octadecynoic acid in LipidPedia. Due to lack of full text of references or no associated biomedical terms are recognized in our current text-mining method, we cannot extract any biomedical terms related to diseases, pathways, locations, functions, genes, lipids, and animal models from the associated reference collection.
Users can download the reference list at the bottom of this page and read the reference manually to find out biomedical information.
Here are additional resources we collected from PubChem and MeSH for 7-octadecynoic acid
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with 7-octadecynoic acid
All references with 7-octadecynoic acid
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Geoffroy V et al. | High bone resorption in adult aging transgenic mice overexpressing cbfa1/runx2 in cells of the osteoblastic lineage. | 2002 | Mol. Cell. Biol. | pmid:12167715 |
| Corey E et al. | Establishment and characterization of osseous prostate cancer models: intra-tibial injection of human prostate cancer cells. | 2002 | Prostate | pmid:11992617 |
| Gruber R et al. | Platelet-released supernatants stimulate formation of osteoclast-like cells through a prostaglandin/RANKL-dependent mechanism. | 2002 | Bone | pmid:11996911 |
| de Hooge AS et al. | Adenoviral transfer of murine oncostatin M elicits periosteal bone apposition in knee joints of mice, despite synovial inflammation and up-regulated expression of interleukin-6 and receptor activator of nuclear factor-kappa B ligand. | 2002 | Am. J. Pathol. | pmid:12000725 |
| Inoue D and Matsumoto T | [Recent advances in basic research of bone metabolism]. | 2002 | Nippon Rinsho | pmid:11979916 |
| Suzuki Y et al. | [Bone destruction and bone loss in rheumatoid arthritis--mechanism, prevention and treatment]. | 2002 | Nippon Rinsho | pmid:11979937 |
| Nakamura H et al. | Localization of osteoprotegerin (OPG) on bone surfaces and cement lines in rat tibia. | 2002 | J. Histochem. Cytochem. | pmid:12070273 |
| Brändström H et al. | A single nucleotide polymorphism in the promoter region of the human gene for osteoprotegerin is related to vascular morphology and function. | 2002 | Biochem. Biophys. Res. Commun. | pmid:12054556 |
| Wittrant Y et al. | Osteoprotegerin differentially regulates protease expression in osteoclast cultures. | 2002 | Biochem. Biophys. Res. Commun. | pmid:12054560 |
| Penno H et al. | Osteoprotegerin secretion from prostate cancer is stimulated by cytokines, in vitro. | 2002 | Biochem. Biophys. Res. Commun. | pmid:12054622 |
| Fu M et al. | Activation of peroxisome proliferator-activated receptor gamma inhibits osteoprotegerin gene expression in human aortic smooth muscle cells. | 2002 | Biochem. Biophys. Res. Commun. | pmid:12056809 |
| Kim YH et al. | Inhibitory action of bisphosphonates on bone resorption does not involve the regulation of RANKL and OPG expression. | 2002 | Exp. Mol. Med. | pmid:12085990 |
| Hofbauer LC and Schoppet M | Osteoprotegerin gene polymorphism and the risk of osteoporosis and vascular disease. | 2002 | J. Clin. Endocrinol. Metab. | pmid:12213849 |
| Arko B et al. | Sequence variations in the osteoprotegerin gene promoter in patients with postmenopausal osteoporosis. | 2002 | J. Clin. Endocrinol. Metab. | pmid:12213850 |
| Rubin J et al. | IGF-I regulates osteoprotegerin (OPG) and receptor activator of nuclear factor-kappaB ligand in vitro and OPG in vivo. | 2002 | J. Clin. Endocrinol. Metab. | pmid:12213884 |
| Palmqvist P et al. | IL-6, leukemia inhibitory factor, and oncostatin M stimulate bone resorption and regulate the expression of receptor activator of NF-kappa B ligand, osteoprotegerin, and receptor activator of NF-kappa B in mouse calvariae. | 2002 | J. Immunol. | pmid:12218157 |
| Kudo O et al. | Proinflammatory cytokine (TNFalpha/IL-1alpha) induction of human osteoclast formation. | 2002 | J. Pathol. | pmid:12237882 |
| Hofbauer LC et al. | High bone density due to a mutation in LDL-receptor-related protein 5. | 2002 | N. Engl. J. Med. | pmid:12240686 |
| Buckley KA and Fraser WD | Receptor activator for nuclear factor kappaB ligand and osteoprotegerin: regulators of bone physiology and immune responses/potential therapeutic agents and biochemical markers. | 2002 | Ann. Clin. Biochem. | pmid:12564836 |
| Mochizuki S et al. | Osteoclastogenesis inhibitory factor/osteoprotegerin ameliorates the decrease in both bone mineral density and bone strength in immobilized rats. | 2002 | J. Bone Miner. Metab. | pmid:11810411 |
| Childs LM et al. | In vivo RANK signaling blockade using the receptor activator of NF-kappaB:Fc effectively prevents and ameliorates wear debris-induced osteolysis via osteoclast depletion without inhibiting osteogenesis. | 2002 | J. Bone Miner. Res. | pmid:11811549 |
| Bolon B et al. | Osteoprotegerin, an endogenous antiosteoclast factor for protecting bone in rheumatoid arthritis. | 2002 | Arthritis Rheum. | pmid:12483715 |
| Golmia RP et al. | Increased osteoprotegerin and decreased pyridinoline levels in patients with ankylosing spondylitis: comment on the article by Gratacós et al. | 2002 | Arthritis Rheum. | pmid:12483748 |
| Liegibel UM et al. | Concerted action of androgens and mechanical strain shifts bone metabolism from high turnover into an osteoanabolic mode. | 2002 | J. Exp. Med. | pmid:12438430 |
| Bolon B et al. | Duration of bone protection by a single osteoprotegerin injection in rats with adjuvant-induced arthritis. | 2002 | Cell. Mol. Life Sci. | pmid:12440777 |
| Saidenberg Kermanac'h N et al. | Osteoprotegerin and inflammation. | 2002 Apr-Jun | Eur. Cytokine Netw. | pmid:12101070 |
| Jung K et al. | Osteoprotegerin and receptor activator of nuclear factor-kappaB ligand (RANKL) in the serum of healthy adults. | 2002 Jul-Sep | Int. J. Biol. Markers | pmid:12408468 |
| Younes A and Aggarwall BB | Clinical implications of the tumor necrosis factor family in benign and malignant hematologic disorders. | 2003 | Cancer | pmid:12879461 |
| Stolina M et al. | Regulatory effects of osteoprotegerin on cellular and humoral immune responses. | 2003 | Clin. Immunol. | pmid:14697750 |
| Kapczuk K et al. | [Osteoprotegerin/RANKL/RANK system and postmenopausal osteoporosis. The possible therapeutic aspects]. | 2003 | Ginekol. Pol. | pmid:12916277 |
| Liu JZ et al. | [Co-expression of human bone morphogenetic protein-2 and osteoprotegerin in myoblast C2C12]. | 2003 | Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi | pmid:12916296 |
| Bendre MS et al. | Interleukin-8 stimulation of osteoclastogenesis and bone resorption is a mechanism for the increased osteolysis of metastatic bone disease. | 2003 | Bone | pmid:12919697 |
| Tabb MM et al. | Vitamin K2 regulation of bone homeostasis is mediated by the steroid and xenobiotic receptor SXR. | 2003 | J. Biol. Chem. | pmid:12920130 |
| Park HR et al. | Expression of osteoprotegerin and RANK ligand in breast cancer bone metastasis. | 2003 | J. Korean Med. Sci. | pmid:12923331 |
| Naylor KE et al. | Serum osteoprotegerin as a determinant of bone metabolism in a longitudinal study of human pregnancy and lactation. | 2003 | J. Clin. Endocrinol. Metab. | pmid:14602774 |
| Paloneva J et al. | DAP12/TREM2 deficiency results in impaired osteoclast differentiation and osteoporotic features. | 2003 | J. Exp. Med. | pmid:12925681 |
| Fukushima H et al. | Expression and role of RANKL in periodontal ligament cells during physiological root-resorption in human deciduous teeth. | 2003 | Eur. J. Oral Sci. | pmid:12887401 |
| Ito R et al. | Expression of osteoprotegerin correlates with aggressiveness and poor prognosis of gastric carcinoma. | 2003 | Virchows Arch. | pmid:12838418 |
| Hayashi S et al. | Distinct osteoclast precursors in the bone marrow and extramedullary organs characterized by responsiveness to Toll-like receptor ligands and TNF-alpha. | 2003 | J. Immunol. | pmid:14607912 |
| Terpos E et al. | Tartrate-resistant acid phosphatase isoform 5b: a novel serum marker for monitoring bone disease in multiple myeloma. | 2003 | Int. J. Cancer | pmid:12845688 |
| Padigel UM et al. | TRANCE-RANK costimulation is required for IL-12 production and the initiation of a Th1-type response to Leishmania major infection in CD40L-deficient mice. | 2003 | J. Immunol. | pmid:14607948 |
| Schett G et al. | Osteoprotegerin protects against generalized bone loss in tumor necrosis factor-transgenic mice. | 2003 | Arthritis Rheum. | pmid:12847699 |
| Gruber HE and Rude RK | Alterations in osteoclast morphology following osteoprotegerin administration in the magnesium-deficient mouse. | 2003 | Biotech Histochem | pmid:14989640 |
| Wagner TU et al. | The teleost fish medaka (Oryzias latipes) as genetic model to study gravity dependent bone homeostasis in vivo. | 2003 | Adv Space Res | pmid:15000082 |
| Ha H et al. | Lipid rafts are important for the association of RANK and TRAF6. | 2003 | Exp. Mol. Med. | pmid:14508068 |
| Miyahira Y et al. | Cutting edge: a potent adjuvant effect of ligand to receptor activator of NF-kappa B gene for inducing antigen-specific CD8+ T cell response by DNA and viral vector vaccination. | 2003 | J. Immunol. | pmid:14662831 |
| Seidlova-Wuttke D et al. | Evidence for selective estrogen receptor modulator activity in a black cohosh (Cimicifuga racemosa) extract: comparison with estradiol-17beta. | 2003 | Eur. J. Endocrinol. | pmid:14514351 |
| Hortobagyi GN | Novel approaches to the management of bone metastases. | 2003 | Semin. Oncol. | pmid:14613037 |
| Voskaridou E et al. | Pamidronate is an effective treatment for osteoporosis in patients with beta-thalassaemia. | 2003 | Br. J. Haematol. | pmid:14616979 |
| Uemura H et al. | Circulating osteoprotegerin in women during GnRH-agonist treatment and their relationships with mineral components and biomarkers of bone turnover. | 2003 | Bone | pmid:14623063 |
| Novack DV | TSH, the bone suppressing hormone. | 2003 | Cell | pmid:14567908 |
| Abe E et al. | TSH is a negative regulator of skeletal remodeling. | 2003 | Cell | pmid:14567913 |
| Zhao ZM et al. | [The preliminary study on in vitro differentiation of human umbilical cord blood cells into neural cells]. | 2003 | Zhonghua Xue Ye Xue Za Zhi | pmid:14575594 |
| Boyan BD et al. | Osteoblasts generate an osteogenic microenvironment when grown on surfaces with rough microtopographies. | 2003 | Eur Cell Mater | pmid:14577052 |
| Zhang J et al. | Soluble receptor activator of nuclear factor kappaB Fc diminishes prostate cancer progression in bone. | 2003 | Cancer Res. | pmid:14633717 |
| Chan BY et al. | Effect of anticoagulants and storage temperature on the stability of receptor activator for nuclear factor-kappa B ligand and osteoprotegerin in plasma and serum. | 2003 | Clin. Chem. | pmid:14633883 |
| Kanatani M et al. | Effect of high phosphate concentration on osteoclast differentiation as well as bone-resorbing activity. | 2003 | J. Cell. Physiol. | pmid:12767054 |
| Ha H et al. | Membrane rafts play a crucial role in receptor activator of nuclear factor kappaB signaling and osteoclast function. | 2003 | J. Biol. Chem. | pmid:12637570 |
| Dovio A et al. | Correspondence re: A. Lipton et al., Serum osteoprotegerin levels in healthy controls and cancer patients. Clin. Cancer Res., 8: 2306-2310, 2002. | 2003 | Clin. Cancer Res. | pmid:12796409 |
| Flick LM et al. | Effects of receptor activator of NFkappaB (RANK) signaling blockade on fracture healing. | 2003 | J. Orthop. Res. | pmid:12798068 |
| Khapli SM et al. | IL-3 acts directly on osteoclast precursors and irreversibly inhibits receptor activator of NF-kappa B ligand-induced osteoclast differentiation by diverting the cells to macrophage lineage. | 2003 | J. Immunol. | pmid:12816992 |
| Kawase Y et al. | Bone malformations in interleukin-18 transgenic mice. | 2003 | J. Bone Miner. Res. | pmid:12817749 |
| Kikuchi T et al. | Cot/Tpl2 is essential for RANKL induction by lipid A in osteoblasts. | 2003 | J. Dent. Res. | pmid:12821717 |
| D'Elia HF et al. | Hormone replacement therapy in rheumatoid arthritis is associated with lower serum levels of soluble IL-6 receptor and higher insulin-like growth factor 1. | 2003 | Arthritis Res. Ther. | pmid:12823855 |
| Knudsen ST et al. | Increased plasma concentrations of osteoprotegerin in type 2 diabetic patients with microvascular complications. | 2003 | Eur. J. Endocrinol. | pmid:12824864 |
| Fox SW et al. | The possible role of TGF-beta-induced suppressors of cytokine signaling expression in osteoclast/macrophage lineage commitment in vitro. | 2003 | J. Immunol. | pmid:12646633 |
| Varsani H et al. | Synovial dendritic cells in juvenile idiopathic arthritis (JIA) express receptor activator of NF-kappaB (RANK). | 2003 | Rheumatology (Oxford) | pmid:12649407 |
| Wise GE et al. | Regulation of osteoprotegerin gene expression in dental follicle cells. | 2003 | J. Dent. Res. | pmid:12651935 |
| Schoppet M et al. | Low serum levels of soluble RANK ligand are associated with the presence of coronary artery disease in men. | 2003 | Circulation | pmid:12654623 |
| Nimmanapalli R and Bhalla K | Targets in apoptosis signaling: promise of selective anticancer therapy. | 2003 | Methods Mol. Biol. | pmid:12777745 |
| Bell NH | RANK ligand and the regulation of skeletal remodeling. | 2003 | J. Clin. Invest. | pmid:12697730 |
| Eghbali-Fatourechi G et al. | Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. | 2003 | J. Clin. Invest. | pmid:12697741 |
| Enomoto H et al. | Induction of osteoclast differentiation by Runx2 through receptor activator of nuclear factor-kappa B ligand (RANKL) and osteoprotegerin regulation and partial rescue of osteoclastogenesis in Runx2-/- mice by RANKL transgene. | 2003 | J. Biol. Chem. | pmid:12697767 |
| Nakashima T et al. | RANKL and RANK as novel therapeutic targets for arthritis. | 2003 | Curr Opin Rheumatol | pmid:12707582 |
| Johnson-Pais TL et al. | Determination of a minimal region of loss of heterozygosity on chromosome 18q21.33 in osteosarcoma. | 2003 | Int. J. Cancer | pmid:12673693 |
| Zaidi M et al. | Osteoclastogenesis, bone resorption, and osteoclast-based therapeutics. | 2003 | J. Bone Miner. Res. | pmid:12674320 |
| Tanaka S et al. | Signal transduction pathways regulating osteoclast differentiation and function. | 2003 | J. Bone Miner. Metab. | pmid:12720046 |
| Valleala H et al. | Effect of cyclical intermittent etidronate therapy on circulating osteoprotegerin levels in patients with rheumatoid arthritis. | 2003 | Eur. J. Endocrinol. | pmid:12720535 |
| Yonou H et al. | Osteoprotegerin/osteoclastogenesis inhibitory factor decreases human prostate cancer burden in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice. | 2003 | Cancer Res. | pmid:12727825 |
| Capparelli C et al. | Sustained antiresorptive effects after a single treatment with human recombinant osteoprotegerin (OPG): a pharmacodynamic and pharmacokinetic analysis in rats. | 2003 | J. Bone Miner. Res. | pmid:12733724 |
| Wong T et al. | Therapeutic implications for interferon-alpha in arthritis: a pilot study. | 2003 | J. Rheumatol. | pmid:12734885 |
| Al-Qawasmi RA et al. | Genetic predisposition to external apical root resorption in orthodontic patients: linkage of chromosome-18 marker. | 2003 | J. Dent. Res. | pmid:12709501 |
| Fujita D et al. | Prostaglandin E2 induced the differentiation of osteoclasts in mouse osteoblast-depleted bone marrow cells. | 2003 | Prostaglandins Leukot. Essent. Fatty Acids | pmid:12711253 |
| Xing L et al. | Expression of either NF-kappaB p50 or p52 in osteoclast precursors is required for IL-1-induced bone resorption. | 2003 | J. Bone Miner. Res. | pmid:12568403 |
| Cao J et al. | Expression of RANKL and OPG correlates with age-related bone loss in male C57BL/6 mice. | 2003 | J. Bone Miner. Res. | pmid:12568404 |
| Johnson-Pais TL et al. | Identification of a novel tandem duplication in exon 1 of the TNFRSF11A gene in two unrelated patients with familial expansile osteolysis. | 2003 | J. Bone Miner. Res. | pmid:12568416 |
| Clohisy JC et al. | RANKL is an essential cytokine mediator of polymethylmethacrylate particle-induced osteoclastogenesis. | 2003 | J. Orthop. Res. | pmid:12568950 |
| Fahrleitner A et al. | Serum osteoprotegerin is a major determinant of bone density development and prevalent vertebral fracture status following cardiac transplantation. | 2003 | Bone | pmid:12584041 |
| Lanzi R et al. | GH replacement therapy increases plasma osteoprotegerin levels in GH-deficient adults. | 2003 | Eur. J. Endocrinol. | pmid:12590637 |
| Shipman CM and Croucher PI | Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells. | 2003 | Cancer Res. | pmid:12615702 |
| Hamzei M et al. | Osteoclast stimulating and differentiating factors in human cholesteatoma. | 2003 | Laryngoscope | pmid:12616193 |
| Siggelkow H et al. | Cytokines, osteoprotegerin, and RANKL in vitro and histomorphometric indices of bone turnover in patients with different bone diseases. | 2003 | J. Bone Miner. Res. | pmid:12619938 |
| Toraldo G et al. | IL-7 induces bone loss in vivo by induction of receptor activator of nuclear factor kappa B ligand and tumor necrosis factor alpha from T cells. | 2003 | Proc. Natl. Acad. Sci. U.S.A. | pmid:12490655 |
| Choi BK et al. | Induction of osteoclastogenesis and matrix metalloproteinase expression by the lipooligosaccharide of Treponema denticola. | 2003 | Infect. Immun. | pmid:12496170 |
| Takayanagi H | [Signaling mechanism in the regulation of osteoclast differentiation by the immune system]. | 2003 | Seikagaku | pmid:14748148 |
| Chen X et al. | Effects of genistein on expression of bone markers during MC3T3-E1 osteoblastic cell differentiation. | 2003 | J. Nutr. Biochem. | pmid:12873716 |
| Bridgham JT and Johnson AL | Characterization of chicken TNFR superfamily decoy receptors, DcR3 and osteoprotegerin. | 2003 | Biochem. Biophys. Res. Commun. | pmid:12878204 |
| Riggs BL et al. | Evidence that type I osteoporosis results from enhanced responsiveness of bone to estrogen deficiency. | 2003 | Osteoporos Int | pmid:12879223 |
| Sasaki T | Differentiation and functions of osteoclasts and odontoclasts in mineralized tissue resorption. | 2003 | Microsc. Res. Tech. | pmid:12879416 |
| Helfrich MH | Osteoclast diseases. | 2003 | Microsc. Res. Tech. | pmid:12879419 |